CSBR

MKT CAP:$83M

Champions Oncology, Inc.

Market Cap

$83M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.80-$0.86 (-12.91%)

Apr 24, 2026

Company Details

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care base...

CEO

Robert Brainin

IPO Date

Feb 2, 2007

Website

www.championsoncology.com

Key Metrics TTM

Revenue

$59M

+15.1% YoY

Net Income

$3M

EPS (Diluted)

$0.21

Free Cash Flow

$5M

Revenue / Share

$4.28

Gross Margin

46.7%

Operating Margin

5.6%

Net Margin

5.2%

FCF Margin

8.9%

P/S

1.4x

P/E

26.8x

Earnings Reports

Q3 2026

Mar 12, 2026

$17M-2.8%EPS -$0.02

FY 2025

Jul 23, 2025

$57M+13.5%EPS $0.33

Q4 2025

Jul 23, 2025

$12M-11.8%EPS -$0.13

Q3 2025

Mar 17, 2025

$17M+41.8%EPS $0.31

Q2 2025

Dec 16, 2024

$13M+16.6%EPS $0.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$12M	$6M	$263.0K
Q3 22	$13M	$7M	$830.0K
Q4 22	$13M	$7M	-$311.0K
Q1 23	$14M	$7M	-$284.0K
Q2 23	$14M	$7M	$7.0K
Q3 23	$13M	$5M	-$2M
Q4 23	$13M	$6M	-$2M
Q1 24	$13M	$5M	-$3M
Q2 24	$12M	$5M	-$2M
Q3 24	$12M	$4M	-$3M
Q4 24	$14M	$7M	$164.0K
Q1 25	$14M	$7M	$1M
Q2 25	$13M	$6M	$732.0K
Q3 25	$17M	$10M	$4M
Q4 25	$12M	$5M	-$2M
Q3 26	$17M	$7M	-$187.0K

Valuation

Quarter	P/S	P/E
Q2 22	1.9x	228.9x
Q3 22	1.8x	202.7x
Q4 22	1.7x	152.0x
Q1 23	1.6x	207.8x
Q2 23	1.5x	771.5x
Q3 23	1.6x	—
Q4 23	1.5x	—
Q1 24	1.6x	—
Q2 24	1.7x	—
Q3 24	1.7x	—
Q4 24	1.7x	—
Q1 25	1.6x	—
Q2 25	1.6x	—
Q3 25	1.4x	13.0x
Q4 25	1.5x	17.7x
Q3 26	1.4x	26.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	$1M	$662.0K
Q3 22	$4M	$4M
Q4 22	$796.0K	$290.0K
Q1 23	-$195.0K	-$949.0K
Q2 23	$3M	$3M
Q3 23	$2M	$819.0K
Q4 23	-$709.0K	-$1M
Q1 24	-$4M	-$5M
Q2 24	$589.0K	$436.0K
Q3 24	-$919.0K	-$1M
Q4 24	-$2M	-$2M
Q1 25	$311.0K	$311.0K
Q2 25	-$283.0K	-$377.0K
Q3 25	$490.0K	$448.0K
Q4 25	$7M	$7M
Q3 26	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q2 22	$566.0K
Q3 22	$405.0K
Q4 22	$506.0K
Q1 23	$754.0K
Q2 23	$604.0K
Q3 23	$754.0K
Q4 23	$760.0K
Q1 24	$668.0K
Q2 24	$153.0K
Q3 24	$126.0K
Q4 24	$111.0K
Q1 25	$0
Q2 25	$94.0K
Q3 25	$42.0K
Q4 25	$253.0K
Q3 26	$37.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+16.5%	+14.0%
Q3 22	+22.0%	+25.8%
Q4 22	+21.9%	+19.7%
Q1 23	+22.1%	+22.8%
Q2 23	+21.2%	+23.9%
Q3 23	-3.2%	+23.2%
Q4 23	+1.5%	+12.1%
Q1 24	-8.6%	+7.7%
Q2 24	-19.0%	-5.2%
Q3 24	-5.9%	-4.2%
Q4 24	+7.1%	-6.4%
Q1 25	+11.9%	-15.8%
Q2 25	+16.6%	-5.7%
Q3 25	+41.8%	-14.1%
Q4 25	-11.8%	+1.7%
Q3 26	+17.8%	+31.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$134.0K	1.1%
Q3 22	$310.0K	2.3%
Q4 22	$188.0K	1.5%
Q1 23	$206.0K	1.5%
Q2 23	$119.0K	0.8%
Q3 23	$331.0K	2.6%
Q4 23	$208.0K	1.6%
Q1 24	$423.0K	3.4%
Q2 24	$53.0K	0.5%
Q3 24	$379.0K	3.2%
Q4 24	$263.0K	1.9%
Q1 25	$258.0K	1.8%
Q2 25	$9.0K	0.1%
Q3 25	$256.0K	1.5%
Q4 25	$131.0K	1.1%
Q3 26	$423.0K	2.6%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 22	$2M	—	—	$4M
Q3 22	$2M	—	—	$4M
Q4 22	$3M	—	—	$4M
Q1 23	$3M	—	—	$4M
Q2 23	$3M	—	—	$4M
Q3 23	$3M	—	—	$4M
Q4 23	$3M	—	—	$5M
Q1 24	$3M	—	—	$5M
Q2 24	$3M	—	—	$4M
Q3 24	$2M	—	—	$5M
Q4 24	$2M	—	—	$5M
Q1 25	$1M	—	—	$4M
Q2 25	$2M	—	—	$3M
Q3 25	$2M	—	—	$4M
Q4 25	$2M	—	—	$4M
Q3 26	$2M	$3M	$3M	—

Revenue Segments

Quarter	Pharmacology Services	Product and Service, Other	Personalized Oncology Services
Q2 22	$11M	$643.0K	—
Q3 22	$13M	$546.0K	$25.0K
Q4 22	$12M	—	—
Q1 23	$13M	$948.0K	$41.0K
Q2 23	$13M	$731.0K	$70.0K
Q3 23	$12M	$648.0K	$6.0K
Q1 24	$12M	$684.0K	$17.0K
Q2 24	$11M	$697.0K	—
Q3 24	$11M	$835.0K	—
Q4 24	$13M	$886.0K	$1.0K
Q1 25	$13M	$992.0K	—
Q2 25	$12M	$991.0K	—
Q4 25	$11M	$831.0K	—
Q3 26	$16M	$375.0K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$9M	$0	$9M
Q1 23	$8M	$0	$8M
Q2 23	$11M	$0	$11M
Q3 23	$12M	$0	$12M
Q4 23	$10M	$0	$10M
Q1 24	$5M	$0	$5M
Q2 24	$6M	$0	$6M
Q3 24	$4M	$0	$4M
Q4 24	$3M	$0	$3M
Q1 25	$3M	$0	$3M
Q2 25	$3M	$0	$3M
Q3 25	$3M	$0	$3M
Q4 25	$10M	$0	$10M
Q1 26	$10M	$0	$10M
Q2 26	$9M	$0	$9M
Q3 26	$7M	$0	$7M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	15M	+8.6%	-3.4%
Q3 22	14M	-1.1%	-0.8%
Q4 22	14M	-6.1%	+0.8%
Q1 23	14M	+0.1%	+0.9%
Q2 23	14M	+0.0%	-7.0%
Q3 23	14M	+0.2%	-5.8%
Q4 23	14M	-0.1%	+0.3%
Q1 24	14M	-0.3%	-0.1%
Q2 24	13M	-0.1%	-0.2%
Q3 24	14M	+0.7%	+0.3%
Q4 24	14M	0.0%	+0.4%
Q1 25	14M	+3.3%	+4.0%
Q2 25	14M	-0.2%	+3.9%
Q3 25	14M	+2.5%	+5.7%
Q4 25	14M	-4.3%	+1.2%
Q3 26	14M	+1.0%	-1.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$60.8K	194
Q3 22	$68.0K	194
Q4 22	$56.0K	230
Q1 23	$59.8K	230
Q2 23	$62.1K	230
Q3 23	$55.5K	230
Q4 23	$56.8K	230
Q1 24	$54.6K	230
Q2 24	$50.3K	230
Q3 24	$52.3K	230
Q4 24	$66.7K	210
Q1 25	$67.0K	210
Q2 25	$64.2K	210
Q3 25	$81.1K	210
Q4 25	$58.0K	213
Q3 26	$77.7K	213

Revenue / Employee